Literature DB >> 8759710

Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step.

T Oravecz1, M Pall, M A Norcross.   

Abstract

The beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta have potent suppressive effects on HIV-1 infection resulting from an early postbinding block in virus fusion and entry. Inhibition was observed only with monocytotropic isolates and mapped to the V3 region of the HIV-1 envelope. RANTES did not inhibit virus expression in chronically infected cells or reduce initial virus attachment to the cell membrane. Inhibitory activity required RANTES binding to the target cell but not G protein-mediated signaling or protein tyrosine kinase activity. The results are consistent with a reversible competitive mechanism of virus inhibition that prevents a V3-associated postbinding step in membrane fusion. The data support a role for a RANTES chemokine receptor as a coreceptor for monocytotropic-HIV-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759710

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Authors:  Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).

Authors:  D Schols; P Proost; J Van Damme; E De Clercq
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

Authors:  Won-Tak Choi; Santhosh Kumar; Navid Madani; Xiaofeng Han; Shaomin Tian; Chang-Zhi Dong; Dongxiang Liu; Srinivas Duggineni; Jian Yuan; Joseph G Sodroski; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-08-29       Impact factor: 3.162

8.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Authors:  M L Penn; J C Grivel; B Schramm; M A Goldsmith; L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

9.  Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.

Authors:  Won-Tak Choi; Shaomin Tian; Chang-Zhi Dong; Santosh Kumar; Dongxiang Liu; Navid Madani; Jing An; Joseph G Sodroski; Ziwei Huang
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 10.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.